JP2021519087A5 - - Google Patents
Info
- Publication number
- JP2021519087A5 JP2021519087A5 JP2020551874A JP2020551874A JP2021519087A5 JP 2021519087 A5 JP2021519087 A5 JP 2021519087A5 JP 2020551874 A JP2020551874 A JP 2020551874A JP 2020551874 A JP2020551874 A JP 2020551874A JP 2021519087 A5 JP2021519087 A5 JP 2021519087A5
- Authority
- JP
- Japan
- Prior art keywords
- cells
- population
- hdaci
- teff
- eff
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2023210666A JP2024037880A (ja) | 2018-03-28 | 2023-12-14 | エフェクターｔ細胞をリプログラムするためのヒストン修飾因子の使用 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862649265P | 2018-03-28 | 2018-03-28 | |
| US62/649,265 | 2018-03-28 | ||
| PCT/US2019/024693 WO2019191501A1 (en) | 2018-03-28 | 2019-03-28 | Use of histone modifiers to reprogram effector t cells |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023210666A Division JP2024037880A (ja) | 2018-03-28 | 2023-12-14 | エフェクターｔ細胞をリプログラムするためのヒストン修飾因子の使用 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2021519087A JP2021519087A (ja) | 2021-08-10 |
| JP2021519087A5 true JP2021519087A5 (https=) | 2022-04-04 |
| JP7447011B2 JP7447011B2 (ja) | 2024-03-11 |
Family
ID=68060769
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020551874A Active JP7447011B2 (ja) | 2018-03-28 | 2019-03-28 | エフェクターｔ細胞をリプログラムするためのヒストン修飾因子の使用 |
| JP2023210666A Pending JP2024037880A (ja) | 2018-03-28 | 2023-12-14 | エフェクターｔ細胞をリプログラムするためのヒストン修飾因子の使用 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023210666A Pending JP2024037880A (ja) | 2018-03-28 | 2023-12-14 | エフェクターｔ細胞をリプログラムするためのヒストン修飾因子の使用 |
Country Status (8)
| Country | Link |
|---|---|
| US (2) | US12173317B2 (https=) |
| EP (2) | EP4722350A2 (https=) |
| JP (2) | JP7447011B2 (https=) |
| KR (1) | KR20200138325A (https=) |
| CN (1) | CN112105368A (https=) |
| AU (1) | AU2019243578B2 (https=) |
| CA (1) | CA3094375A1 (https=) |
| WO (1) | WO2019191501A1 (https=) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1814580B1 (en) | 2004-11-24 | 2016-08-10 | Fred Hutchinson Cancer Research Center | Methods of using il-21 for adoptive immunotherapy and identification of tumor antigens |
| CA3094375A1 (en) * | 2018-03-28 | 2019-10-03 | Board Of Regents, The University Of Texas System | Use of histone modifiers to reprogram effector t cells |
| KR102069704B1 (ko) * | 2018-05-16 | 2020-01-23 | 고려대학교 산학협력단 | Hdac 억제제를 이용한 사람 유래 자연살해세포의 확장 배양법 |
| WO2020069377A1 (en) * | 2018-09-27 | 2020-04-02 | Arizona Board Of Regents On Behalf Of The University Of Arizona | Methods of using lysine deacetylase (kdac) inhibition to generate antigen specific memory t cell responses for durable immunotherapy |
| CA3158133A1 (en) | 2020-04-28 | 2021-11-04 | Lyell Immunopharma, Inc. | Methods for culturing cells |
| EP4159843A4 (en) * | 2020-05-29 | 2024-07-31 | Shanghai Juncell Therapeutics Co., Ltd. | MEDIUM FOR SEEDING CELLS OF TUMOR INFILTRATING LYMPHOCYTES AND ITS APPLICATION |
| GB202008957D0 (en) * | 2020-06-12 | 2020-07-29 | Autolus Ltd | Culture medium |
| CN113502265B (zh) * | 2021-05-25 | 2024-05-28 | 昭泰英基生物医药（香港）有限公司 | 将t细胞重编程为类nk细胞的诱导剂及其应用 |
| US20250248946A1 (en) * | 2022-04-15 | 2025-08-07 | Turn Biotechnologies, Inc. | Methods and compositions for immune cell rejuvenation and therapies using rejuvenated immune cells |
| WO2023215825A1 (en) * | 2022-05-05 | 2023-11-09 | Immatics US, Inc. | Methods for improving t cell efficacy |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6307024B1 (en) | 1999-03-09 | 2001-10-23 | Zymogenetics, Inc. | Cytokine zalpha11 Ligand |
| EP1814580B1 (en) | 2004-11-24 | 2016-08-10 | Fred Hutchinson Cancer Research Center | Methods of using il-21 for adoptive immunotherapy and identification of tumor antigens |
| CA2946312A1 (en) | 2014-04-23 | 2015-10-29 | Juno Therapeutics, Inc. | Methods for isolating, culturing, and genetically engineering immune cell populations for adoptive therapy |
| SG11201811408PA (en) * | 2016-06-24 | 2019-01-30 | Univ Mcmaster | Adoptive cell transfer and oncolytic virus combination therapy |
| TWI908706B (zh) | 2018-03-07 | 2025-12-21 | 美商波西達治療公司 | ＣＡＲＴｙｒｉｎ組成物和使用方法 |
| CA3094375A1 (en) * | 2018-03-28 | 2019-10-03 | Board Of Regents, The University Of Texas System | Use of histone modifiers to reprogram effector t cells |
| AU2019335014A1 (en) * | 2018-09-05 | 2021-03-25 | Poseida Therapeutics, Inc. | Allogeneic cell compositions and methods of use |
-
2019
- 2019-03-28 CA CA3094375A patent/CA3094375A1/en active Pending
- 2019-03-28 EP EP25226324.9A patent/EP4722350A2/en active Pending
- 2019-03-28 KR KR1020207031018A patent/KR20200138325A/ko active Pending
- 2019-03-28 WO PCT/US2019/024693 patent/WO2019191501A1/en not_active Ceased
- 2019-03-28 CN CN201980030423.9A patent/CN112105368A/zh active Pending
- 2019-03-28 US US17/042,022 patent/US12173317B2/en active Active
- 2019-03-28 AU AU2019243578A patent/AU2019243578B2/en active Active
- 2019-03-28 JP JP2020551874A patent/JP7447011B2/ja active Active
- 2019-03-28 EP EP19775917.8A patent/EP3773626B1/en active Active
-
2023
- 2023-12-14 JP JP2023210666A patent/JP2024037880A/ja active Pending
-
2024
- 2024-11-18 US US18/951,341 patent/US20250145953A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2021519087A5 (https=) | ||
| Schneidawind et al. | Regulatory T cells and natural killer T cells for modulation of GVHD following allogeneic hematopoietic cell transplantation | |
| Gattinoni et al. | T memory stem cells in health and disease | |
| Putnam et al. | Clinical grade manufacturing of human alloantigen-reactive regulatory T cells for use in transplantation | |
| RU2017111300A (ru) | Центральные т-клетки памяти для адоптивной т-клеточной терапии | |
| US8685728B2 (en) | Kit containing stem cells and cytokines for use in attenuating immune responses | |
| Kim et al. | Treatment with agonistic DR3 antibody results in expansion of donor Tregs and reduced graft-versus-host disease | |
| Geem et al. | Harnessing regulatory T cells for the treatment of inflammatory bowel disease | |
| Pinchuk et al. | Human colonic myofibroblasts promote expansion of CD4+ CD25high Foxp3+ regulatory T cells | |
| Nardo‐Marino et al. | Emerging therapies in sickle cell disease | |
| Introna et al. | Cytokine Induced Killer (CIK) cells for the treatment of haematological neoplasms | |
| Luz-Crawford et al. | Mesenchymal stem cells direct the immunological fate of macrophages | |
| FI3578201T3 (fi) | Menetelmiä ja koostumuksia luonnollisille tappajasoluille | |
| RU2014110897A (ru) | Т-клетки центральной памяти против третьей стороны, способы их получения и их применение в трансплантации и лечении заболеваний | |
| BR112013003366A2 (pt) | terapia aperfeiçoada de células tronco hematopoiéticas e progenitoras | |
| Hu et al. | Th17/Treg imbalance in inflammatory bowel disease: immunological mechanisms and microbiota-driven regulation | |
| Xu et al. | Immunomodulatory effects of histone deacetylation inhibitors in graft-vs.-host disease after allogeneic stem cell transplantation | |
| Doglio et al. | Cell-based therapy in prophylaxis and treatment of chronic graft-versus-host disease | |
| Osumi et al. | Prospective study of allogeneic hematopoietic stem cell transplantation with post-transplantation cyclophosphamide and antithymocyte globulin from HLA-mismatched related donors for nonmalignant diseases | |
| Koh et al. | Nonmyeloablative allogeneic hematopoietic stem cell transplant using mismatched/haploidentical donors: a review | |
| Gagliani et al. | Rapamycin combined with anti-CD45RB mAb and IL-10 or with G-CSF induces tolerance in a stringent mouse model of islet transplantation | |
| RU2016102172A (ru) | Терапия и способ внутриопухолевого введения цитотоксического т-лимфоцита и/или nkt-клетки с антителом против tnf и/или антителом против il-10 | |
| JP2022023136A5 (https=) | ||
| Ott et al. | Innate immune cellular therapeutics in transplantation | |
| Pierini et al. | Regulatory T cell immunotherapy in immune-mediated diseases |